<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">KETOROLAC TROMETHAMINE</span><br/>(ke-tor'o-lac)<br/><span class="topboxtradename">Toradol, </span><span class="topboxtradename">Acular, </span><span class="topboxtradename">Acular LS<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">nsaid, analgesic</span>; <span class="classification">antipyretic</span><br/><b>Prototype: </b>Ibuprofen<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg tablets; 15 mg/mL, 30 mg/mL injection; 0.4%, 0.5% ophthalmic solution</p>
<h1><a name="action">Actions</a></h1>
<p>It inhibits synthesis of prostaglandins and is a peripherally acting analgesic. Ketorolac does not have any known effects
         on opiate receptors.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Ketorolac exhibits analgesic, antiinflammatory, and antipyretic activity.</p>
<h1><a name="uses">Uses</a></h1>
<p>
<i>Short-term</i> management of pain; ocular itching due to seasonal allergic conjunctivitis, reduction of post-operative pain and photophobia
         after refractive surgery.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ketorolac; individuals with complete or partial syndrome of nasal polyps, angioedema, and bronchospastic
         reaction to aspirin or other <small>NSAID</small>s; during labor and delivery; patients with severe renal impairment or at risk for renal failure due to volume depletion;
         patients with risk of bleeding; active peptic ulcer disease; pre- or intraoperatively; intrathecal or epidural administration;
         in combination with other <small>NSAID</small>s; lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of peptic ulcers; impaired renal or hepatic function; older adults; debilitated patients; pregnancy (category B).
         Safety and effectiveness in children is not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Pain</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV Loading Dose</span> 30 mg (15 mg IM 3060 mg loading dose, then 1530 mg q6h [max: 150 mg/d on first day, then 120 mg subsequent days (30 mg load, then
               15 mg q6h if PO 10 mg q6h prn (max: 40 mg/d) max duration all routes 5 d<br/><span class="rdage">Geriatric:</span> <span class="rdroute">IV Loading Dose</span> 15 mg <span class="rdroute">IM</span> 30 mg loading dose, then 15 mg q6h <span class="rdroute">PO</span> 510 mg q6h prn (max: 40 mg/d) max duration all routes 5 d<br/><br/><span class="indicationtitle">Pain after Refractive Surgery</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Ophthalmic</span>
<i>Acular LS only</i> 1 drop in operative eye q.i.d. up to 4 d<br/><br/><span class="indicationtitle">Allergic Conjunctivitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Ophthalmic</span> 1 drop 0.5% solution q.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p><b><small>WARNING: </small></b></p>
<p>Do not administer IV, IM, or PO ketorolac longer than 5 d.</p><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food to reduce GI effects.</li>
</ul><span class="adminroutetype">Instillation</span><br/><ul>
<li>Do not touch container to the eye when applying ophthalmic drops.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Inject IM drug slowly and deeply into a large muscle.</li>
<li>Rotate injection sites to avoid injection site pain in patients receiving multiple doses.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give IV bolus dose over at least 15 s. Preferred method is to give through a Y-tube in a free-flowing IV.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Y-site:</span>
<b>Azithromycin.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store all forms at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Drowsiness,</span> dizziness, headache. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea,</span> dyspepsia, GI pain, <span class="speceff-life">hemorrhage</span>. <span class="typehead">Other:</span> Edema, sweating, pain at injection site. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase <b>methotrexate</b> levels and toxicity; may increase <b>lithium</b> levels and toxicity. <span class="typehead">Herbal:</span>
<b>Feverfew,</b>
<b>garlic,</b>
<b>ginger,</b>
<b>ginkgo</b> increased bleeding potential. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 4560 min. <span class="typehead">Distribution:</span> Distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 46 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Correct hypovolemia prior to administration of ketorolac.</li>
<li>Lab tests: Periodic serum electrolytes and liver functions; urinalysis (for hematuria and proteinuria) with long-term use.</li>
<li>Monitor urine output in older adults and patients with a history of cardiac decompensation, renal impairment, heart failure,
            or liver dysfunction as well as those taking diuretics. Discontinuation of drug will return urine output to pretreatment level.
         </li>
<li>Monitor for S&amp;S of GI distress or bleeding including nausea, GI pain, diarrhea, melena, or hematemesis. GI ulceration with
            perforation can occur anytime during treatment. Drug decreases platelet aggregation and thus may prolong bleeding time.
         </li>
<li>Monitor for fluid retention and edema in patients with a history of CHF.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Watch for S&amp;S of GI ulceration and bleeding (e.g., bloody emesis, black tarry stools) during long-term therapy.</li>
<li>
            							Note: Possible CNS adverse effects (e.g., light-headedness, dizziness, drowsiness).
            						
         </li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Do not use other <small>NSAID</small>s while taking this drug.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>